BRCA, or BReastCAncer, gene mutations may be hereditary and their presence indicates a higher risk of developing breast cancer, among other types of cancer.
BRCA1 and BRCA2 are genes involved in DNA repair. When either of these genes are altered, DNA repair may not occur correctly, making tumors more likely to appear.
•Ages 18 years and older
•Locally advanced and/or metastatic breast cancer
•Have received no more than three (3) prior cytotoxic chemotherapy regimens in the advanced setting
•Deemed appropriate for single-agent therapy
Breast Cancer & BRCA Facts
•Approximately 12% of women will be diagnosed with breast cancer in their lifetime
•Breast cancer is the most commonly diagnosed cancer in Hispanic women and the leading cause of death
•There is a significantly higher prevalence of the BRCA mutation in people of Mexican and Puerto Rican descent
•As many as 65% of women who genetically inherit a deleterious BRCA mutation will develop breast cancer by the age of 70
•BRCA mutations account for more than 50% of hereditary breast cancers
Talazoparib is a type of anti-cancer drug called a PARP (poly ADP ribose polymerase) inhibitor. PARP is important for normal DNA repair, a process necessary for continued tumor growth. Talazoparib is an investigational product for which safety and efficacy have not been established.
Although there is no guarantee you will benefit from being in this study, your participation may help us better understand this devastating disease and how to treat it. A clinical trial may be an option for patients with BRCA-mutated advanced breast cancer because there are no approved treatments specifically for this high-risk patient population.
For more information about, or to determine your potential eligibility to participate in, the EMBRACA clinical trial, please visit: www.embracastudy.com.
The EMBRACA trial is sponsored by Medivation, a biopharmaceutical company based in San Francisco, Calif., seeking to transform the lives of patients by developing and delivering medically innovative therapies to treat serious diseases for which treatment options are limited, such as advanced breast cancer.